Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

Listed in the December 27, 2023 extract; not in the current extract (Aug 26, 2026): Diastat (09853340), Diastat (09853430). Source: odb-formulary-ed43-extract-2023-12-27.xml; compared with odb-formulary-ed43-extract-2026-08-26.xml.

DIAZEPAM

Form:

10 of 10 products shown

6 general benefit · 1 Limited Use · 3 not a benefit

Other products in the same Health Canada class (N05BA) — coverage varies; not interchangeable

  • Alprazolam (Xanax): general benefit, Not a benefit
  • Bromazepam (Lectopam): general benefit, Not a benefit
  • Chlordiazepoxide (Librium): general benefit, Not a benefit
  • Clorazepate dipotassium (Tranxene): general benefit, Not a benefit
  • Lorazepam (Apo-Lorazepam): general benefit, Not a benefit
  • Oxazepam (Apo-Oxazepam): general benefit, Not a benefit

1 more in the class list below

Diazepam · DIN 00405329 · 2mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Diazepam · DIN 00405329 Manufacturer: A A Pharma Inc.; listing date 1996-10-01 Health Canada: Marketed since 2019-08-27 · brand DIAZEPAM · ATC N05BA01 DIAZEPAM · form Tablet · route Oral · ingredients DIAZEPAM 2 MG · company Aa pharma inc · schedule Targeted substances (cdsa iv)
Check this DIN again · Health Canada product record

Diazepam: Formulary list price $0.0532/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0532 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=3290 · Verify on the e-Formulary ↗ (DIN 00405329)

Source record
DIN 00405329: Diazepam Raw flags: sec3=Y Item: 281608025; group id 488; item number 1248; lccId None; manufacturer id AAP Source form: Tab; strength: 2mg Recorded listing: General benefit Source prices (unrounded): $0.0532; ministry $0.0532 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00405329 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=3290
Interchangeable products
Valium · DIN 00013277 · not recorded
Shortage status: discontinued (2018-09-14, reported by APOTEX INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00405329
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Diazepam Injection USP · DIN 00399728 · 5mg/mL · injection solution (Preservative Free)

Limited Use — Reason for Use code 481 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 481 required
Write on scriptLU code 481 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 481
Reason for Use code 481 For the management of patients receiving palliative care*. Coverage limit: LU Authorization Period: 1 year Coverage limit: *The patient must have a progressive life-limiting illness and require this medication for palliative purposes.
No interchangeable product listed in the Ontario extract
Diazepam Injection USP · DIN 00399728 Manufacturer: Sandoz Canada Inc.; listing date 2017-02-28 Health Canada: Marketed since 2005-09-19 · brand DIAZEPAM INJECTION USP · ATC N05BA01 DIAZEPAM · form Solution · route Intravenous, Intramuscular · ingredients DIAZEPAM 5 MG/ML · company Sandoz canada incorporated · schedule Targeted substances (cdsa iv)
Check this DIN again · Health Canada product record

Diazepam Injection USP: Formulary list price $1.6415/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.6415 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=3721 · Verify on the e-Formulary ↗ (DIN 00399728)

Source record
DIN 00399728: Diazepam Injection USP Raw flags: sec12=Y, sec3=Y Item: 281608205; group id 487; item number 1244; lccId 00274; manufacturer id SDZ Source form: Inj Sol (Preservative Free); strength: 5mg/mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $1.6415; ministry $1.6415 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00399728 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=3721
Shortage status: resolved shortage (ended 2021-01-22); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00399728
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Diastat · DIN 02238162 · 5mg/mL · Rect Gel-2x 5mg Pk

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Diastat · DIN 02238162 Manufacturer: Bausch Health Canada Inc.; listing date 2000-11-30 Health Canada: Marketed since 2021-08-18 · brand DIASTAT · ATC N05BA01 DIAZEPAM · form Gel · route Rectal · ingredients DIAZEPAM 5 MG/1ML · company Bausch health, canada inc. · schedule Targeted substances (cdsa iv)
Check this DIN again · Health Canada product record

Diastat: Formulary list price $218.3106/unit (unit not stated in source; not the patient's cost)

Ministry pays: $218.3106 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=61553 · Verify on the e-Formulary ↗ (DIN 02238162)

Source record
DIN 02238162: Diastat Raw flags: sec3=Y Item: 281608201; group id 488; item number 1245; lccId None; manufacturer id BHC Source form: Rect Gel-2x 5mg Pk; strength: 5mg/mL Recorded listing: General benefit Source prices (unrounded): $218.3106; ministry $218.3106 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02238162 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=61553
Shortage status: resolved shortage (ended 2025-05-13); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02238162
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Diazepam · DIN 00362158 · 5mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Diazepam · DIN 00362158 Manufacturer: A A Pharma Inc.; listing date 1996-10-01 Health Canada: Marketed since 2019-06-13 · brand DIAZEPAM · ATC N05BA01 DIAZEPAM · form Tablet · route Oral · ingredients DIAZEPAM 5 MG · company Aa pharma inc · schedule Targeted substances (cdsa iv)
Check this DIN again · Health Canada product record

Diazepam: Formulary list price $0.1662/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1662 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2657 · Verify on the e-Formulary ↗ (DIN 00362158)

Source record
DIN 00362158: Diazepam Raw flags: sec3=Y Item: 281608024; group id 488; item number 1249; lccId None; manufacturer id AAP Source form: Tab; strength: 5mg Recorded listing: General benefit Source prices (unrounded): $0.1662; ministry $0.1662 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00362158 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2657
Interchangeable products
Valium · DIN 00013285 · not recorded
Shortage status: resolved shortage (ended 2024-01-24); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00362158
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Diastat · DIN 02519070 · 10mg/2mL · Rect Gel-2x10mg Pk

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Diastat · DIN 02519070 Manufacturer: Bausch Health Canada Inc.; listing date 2025-12-30 Health Canada: Marketed since 2022-04-21 · brand DIASTAT · ATC N05BA01 DIAZEPAM · form Gel · route Rectal · ingredients DIAZEPAM 10 MG/2ML · company Bausch health, canada inc. · schedule Targeted substances (cdsa iv)
Check this DIN again · Health Canada product record

Diastat: Formulary list price $218.3106/unit (unit not stated in source; not the patient's cost)

Ministry pays: $218.3106 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100835 · Verify on the e-Formulary ↗ (DIN 02519070)

Source record
DIN 02519070: Diastat Raw flags: sec3=Y Item: 281608202; group id 488; item number 1246; lccId None; manufacturer id BHC Source form: Rect Gel-2x10mg Pk; strength: 10mg/2mL Recorded listing: General benefit Source prices (unrounded): $218.3106; ministry $218.3106 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02519070 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100835
Shortage status: resolved shortage (ended 2025-12-15); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02519070
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Diazepam · DIN 00405337 · 10mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Diazepam · DIN 00405337 Manufacturer: A A Pharma Inc.; listing date 1996-10-01 Health Canada: Marketed since 2020-05-07 · brand DIAZEPAM · ATC N05BA01 DIAZEPAM · form Tablet · route Oral · ingredients DIAZEPAM 10 MG · company Aa pharma inc · schedule Targeted substances (cdsa iv)
Check this DIN again · Health Canada product record

Diazepam: Formulary list price $0.1204/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1204 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=3291 · Verify on the e-Formulary ↗ (DIN 00405337)

Source record
DIN 00405337: Diazepam Raw flags: sec3=Y Item: 281608023; group id 488; item number 1250; lccId None; manufacturer id AAP Source form: Tab; strength: 10mg Recorded listing: General benefit Source prices (unrounded): $0.1204; ministry $0.1204 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00405337 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=3291
Interchangeable products
Valium · DIN 00013293 · not recorded
Shortage status: active shortage (reported 2026-09-01, estimated to end 2026-10-23, last updated 2026-09-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00405337
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Diastat · DIN 02519089 · 15mg/3mL · Rect Gel-2x15mg Pk

General benefitMarketed · checked 2026-09-19
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Diastat · DIN 02519089 Manufacturer: Bausch Health Canada Inc.; listing date 2025-12-30 Health Canada: Marketed since 2022-04-21 · brand DIASTAT · ATC N05BA01 DIAZEPAM · form Gel · route Rectal · ingredients DIAZEPAM 15 MG/3ML · company Bausch health, canada inc. · schedule Targeted substances (cdsa iv)
Check this DIN again · Health Canada product record

Diastat: Formulary list price $218.3106/unit (unit not stated in source; not the patient's cost)

Ministry pays: $218.3106 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100836 · Verify on the e-Formulary ↗ (DIN 02519089)

Source record
DIN 02519089: Diastat Raw flags: sec3=Y Item: 281608203; group id 488; item number 1247; lccId None; manufacturer id BHC Source form: Rect Gel-2x15mg Pk; strength: 15mg/3mL Recorded listing: General benefit Source prices (unrounded): $218.3106; ministry $218.3106 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02519089 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100836
Shortage status: resolved shortage (ended 2025-05-13); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02519089
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Valium · DIN 00013285 · 5mg · tablet

Listed, not a benefitMarketed · checked 2026-09-19
StatusListed, not a benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Valium · DIN 00013285 Manufacturer: Hoffmann-La Roche Limited; listing date 1996-10-01 Health Canada: Marketed since 2024-11-01 · brand VALIUM · ATC N05BA01 DIAZEPAM · form Tablet · route Oral · ingredients DIAZEPAM 5 MG · company Searchlight pharma inc · schedule Targeted substances (cdsa iv)
Check this DIN again · Health Canada product record

Valium: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=3178 · Verify on the e-Formulary ↗ (DIN 00013285)

Source record
DIN 00013285: Valium Raw flags: notABenefit=Y, sec3=Y Item: 281608024; group id 488; item number 1249; lccId None; manufacturer id HLR Source form: Tab; strength: 5mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00013285 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=3178
Interchangeable products
Diazepam · DIN 00362158 · $0.1662
Shortage status: resolved shortage (ended 2024-10-09); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00013285
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Valium · PIN 00013277 · 2mg · tablet

Listed, not a benefitOntario PIN; no Health Canada record under this code
StatusListed, not a benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.

No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Health Canada record for this brand: DIN 00013285 (Marketed, 2024-11-01) Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=3178

Check Health Canada brand DIN
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Valium · DIN 00013277 Manufacturer: Hoffmann-La Roche Limited; listing date 2005-02-22 No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Health Canada record for this brand: DIN 00013285 (Marketed, 2024-11-01) Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=3178
Check this DIN again

Valium: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Ontario PIN; see Health Canada brand lookup · Verify on the e-Formulary ↗ (DIN 00013277)

Source record
DIN 00013277: Valium Raw flags: notABenefit=Y, sec3=Y Item: 281608025; group id 488; item number 1248; lccId None; manufacturer id HLR Source form: Tab; strength: 2mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00013277 Health Canada record for this brand: DIN 00013285 (Marketed, 2024-11-01) Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=3178
Interchangeable products
Diazepam · DIN 00405329 · $0.0532
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00013277
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Valium · DIN 00013293 · 10mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2001-07-19 — choose a marketed DIN from the same-category list.Discontinued 2001-07-19 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2001-07-19 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2001-07-19 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Valium · DIN 00013293 Manufacturer: Hoffmann-La Roche Limited; listing date 1996-10-01 Health Canada: Cancelled post market since 2001-07-19 · brand VALIUM 10 TAB · ATC N05BA01 DIAZEPAM · form Tablet · route Oral · ingredients DIAZEPAM 10 MG · company Hoffmann-la roche limited · schedule Targeted substances (cdsa iv)
Check this DIN again · Health Canada product record

Valium: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=3179 · Verify on the e-Formulary ↗ (DIN 00013293)

Source record
DIN 00013293: Valium Raw flags: notABenefit=Y, sec3=Y Item: 281608023; group id 488; item number 1250; lccId None; manufacturer id HLR Source form: Tab; strength: 10mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00013293 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=3179
Interchangeable products
Diazepam · DIN 00405337 · $0.1204
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00013293
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2001-07-19 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (28:16:08 Tranquilizers) and how they are covered

Matched class: 28:16:08 Tranquilizers

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ARIPIPRAZOLE, ASENAPINE, BREXPIPRAZOLE, CARIPRAZINE, FLUPENTIXOL DECANOATE, FLUPENTIXOL DIHYDROCHLORIDE, PALIPERIDONE, PALIPERIDONE PALMITATE, PERICYAZINE, PIMOZIDE, ZIPRASIDONE HCL MONOHYDRATE, ZUCLOPENTHIXOL DECANOATE, ZUCLOPENTHIXOL DIHYDROCHLORIDE Some products covered without a code (check the product listing): ALPRAZOLAM, BROMAZEPAM, CHLORDIAZEPOXIDE, CHLORPROMAZINE, CLORAZEPATE DIPOTASSIUM, FLUPHENAZINE HCL, HALOPERIDOL, HALOPERIDOL DECANOATE, LORAZEPAM, LOXAPINE SUCCINATE, LURASIDONE HYDROCHLORIDE, OLANZAPINE, OXAZEPAM, PERPHENAZINE, PROCHLORPERAZINE, QUETIAPINE, RISPERIDONE, TRIFLUOPERAZINE 28:16:08 Tranquilizers

ALPRAZOLAM

· 12 products · General benefit (6), Off-Formulary Interchangeable, not an ODB benefit (6) · strengths: 0.25mg, 0.5mg, 1mg, 2mg · Tab

BROMAZEPAM

· 8 products · Listed, not a benefit (3), General benefit (5) · strengths: 1.5mg, 3mg, 6mg · Tab

CHLORDIAZEPOXIDE

· 6 products · Listed, not a benefit (3), General benefit (3) · strengths: 5mg, 10mg, 25mg · Cap

CLORAZEPATE DIPOTASSIUM

· 6 products · Listed, not a benefit (3), General benefit (3) · strengths: 3.75mg, 7.5mg, 15mg · Cap

LORAZEPAM

· 12 products · General benefit (9), Listed, not a benefit (3) · strengths: 0.5mg, 1mg, 2mg · Tab

OXAZEPAM

· 6 products · General benefit (3), Listed, not a benefit (3) · strengths: 10mg, 15mg, 30mg · Tab

HYDROXYZINE HCL

· 8 products · Listed, not a benefit · strengths: 10mg, 25mg, 50mg · Cap

ARIPIPRAZOLE

· 70 products · General benefit · strengths: 720mg/2.4mL, 960mg/3.2mL, 300mg/Vial, 400mg/Vial, 2mg, 5mg, 10mg, 15mg, 20mg, 30mg · Inj Sol-Pref Syr, Prolong-Rel Inj Pd-Vial Pk, Tab

ASENAPINE

· 2 products · General benefit · strengths: 5mg, 10mg · SL Tab

BREXPIPRAZOLE

· 6 products · General benefit · strengths: 0.25mg, 0.5mg, 1mg, 2mg, 3mg, 4mg · Tab

CARIPRAZINE

· 4 products · General benefit · strengths: 1.5mg, 3mg, 4.5mg, 6mg · Cap

CHLORPROMAZINE

· 6 products · General benefit (3), Listed, not a benefit (3) · strengths: 25mg, 50mg, 100mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:16:08 and 21 more
Full class listing Related classes: 28:08:04 Nonsteroidal Anti-Inflammatory Agents, 28:08:08 Opiate Agonists, 28:08:12 Opiate Partial Agonists, 28:08:92 Miscellaneous Analgesics and Antipyretics, 28:16:04 Antidepressants, 28:16:12 Other Psychotropics, 28:36:08 Anticholinergic Agents, 28:36:20 Dopamine Receptor Agonists Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE VALIUM (diazepam) is useful in the symptomatic management of mild to moderate degrees of anxiety in conditions dominated by tension, excitation, agitation, fear or aggressiveness, such as may occur in: psychoneurosis, anxiety reactions due to stress conditions and anxiety states with somatic expression. In acute alcoholic withdrawal, VALIUM may be useful in the symptomatic relief of acute agitation, tremor and impending acute delirium tremens. VALIUM is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathology, such as inflammation of the muscle and joints or secondary to trauma; spasticity caused by upper motor neuron disorders, such as cerebral palsy and paraplegia; athetosis and the rare "stiff man syndrome". Geriatrics Elderly and debilitated patients are especially susceptible to dose-related adverse events and a reduced dose is recommended. Long-term use of VALIUM should be avoided in elderly patients. Enhanced monitoring is recommended (see WARNINGS AND PRECAUTIONS, Falls and fractures; DOSAGE AND ADMINISTRATION, Dosing considerations). Pediatrics VALIUM is contraindicated in children under 6 months (see… https://pdf.hres.ca/dpd_pm/00071024.PDF PM date: MAY 24, 2023 Source product: VALIUM; DIN 00013285; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Diazepam · DIN 00405329 Shortage status: discontinued (2018-09-14, reported by APOTEX INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00405329

Check this DIN again

Diazepam · DIN 00405337 Shortage status: active shortage (reported 2026-09-01, estimated to end 2026-10-23, last updated 2026-09-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00405337

Check this DIN again

Other review policies

For Valium: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026